All right, thank you Marcus. Let's turn to Slide 12. As I mentioned earlier, our immediate focus is on tariff mitigation actions. As mentioned earlier, we have organized these initiatives into three key areas customer advocacy, market diversification and operational adjustments. I'll expand further on these mitigation strategies on the following slide. Though we remain committed to our key strategic initiatives, progress for some of these initiatives will likely be paused this year. For example, debt reduction in 2025, will likely be minimal due to the cash flow uncertainty, caused by the tariff situation. Also, in the Cellulose Commodities segment, we will likely increase the production of non-fluff commodities in the short-term, to keep the plants operating at capacity, while we work to mitigate the impact of the tariffs. Conversely, we plan to continue to pursue high return, but low risk strategic investments that will improve operational efficiencies. We also believe that the change in the macroeconomic climate doesn't it affect the investment thesis, of our biomaterials growth strategy given that the investments in commerce will be U.S. centric. So we will continue to execute our biomaterials strategy. The strategy's key projects will continue to advance, and we expect to make final investment decisions on several projects in the second half of this year. Moving to Slide 13, currently within our Cellulose Commodities segment, only our fluff pulp sales to China, are directly subject to tariffs. In addition though, we expect some indirect secondary impact from a few U.S. cellulose specialty customers that are also facing high tariffs into China. To address this challenge, we are actively diversifying our sales channels into non-tariff affected markets, taking immediate steps to gradually shift production toward other commodity grades, and engaging in ongoing dialogues with customers to mitigate disruptions. We remain closely attuned to the evolving trade landscape, and will continue to proactively take steps to further protect our market position. Though our paperboard products are USMCA compliant, thus currently avoid tariffs, we are proactively working to reduce our exposure to potential future tariffs. For example, we are taking advantage of the current buy Canada sentiment, to increase our Canadian market share, and the Canadian government is positioned to impose retaliatory tariffs on U.S. paperboard products if needed. On Slide 14, we outline our updated financial guidance and cash flow drivers for 2025. As already noted, our adjusted EBITDA guidance is now in the range of $175 million to $185 million, which is roughly a $45 million reduction from the midpoint of our earlier guidance. The primary drivers of this lower EBITDA guidance include the following: we now assume a $20 million reduction in adjusted EBITDA from tariff related impacts, specifically the estimated direct impact on cellulose commodities, and secondarily to our CS customers. We also lowered the adjusted EBITDA guidance by $15 million, to reflect our first quarter production problems, which we believe are largely behind us as the scheduled maintenance outages, for all the HPC plants were completed in March and April. The new guidance also includes a $12 million non-cash environmental charge in corporate expenses. However, most of the actual cash spend for this charge, will not occur before 2028. We are forecasting unfavorable foreign exchange adjustment of $5 million, due to the weakened U.S. dollar, versus both the Canadian dollar and euro, and we are forecasting input prices, to remain largely in line with our prior guidance. Finally, some CS orders were canceled, or delayed in April after the initial tariffs were announced. Though we expect that most of these orders will be rebooked. This revenue and accompanying EBITDA, will likely be recognized in the second half of the year. Consequently, the second quarter results will be lower than a straight linear extrapolation. Adjusted free cash flow guidance, is expected to be in the range of $5 million to $15 million. Cash interest expense is projected to be approximately $93 million, which is $12 million higher than normal, due to the timing of interest payments related to our recent debt refinancing. Maintenance capital expenditure remains at $85 million, primarily driven by the extended planned maintenance outages at our HPC facilities, which as noted are largely behind us. The pause of $10 million under environmental, and other reflected non-cash environmental reserve charge discussed earlier. Working capital is expected to contribute an additional $5 million. And lastly, we have reduced our expected cash outflows related to the France deferred energy payments to $5 million, due to timing. On Slide 15, we summarize the 2025 market outlook across each of our business segments in greater detail. In cellulose specialties, we anticipate a mid-single-digit percentage price increase, versus 2024 driven by our ongoing value over volume strategy. We believe that ether's demand will improve, and other CS sales volumes will remain robust. However, asset volumes face ongoing destocking pressures and as I've noted, we acknowledge that asset demand could present additional near term risk, as customers leverage the tariff related pause, in orders during April, to accelerate the achievement of their destocking objective. Although this could intensify near term volume impacts, we believe that such actions, would expedite the destocking process creating a healthier market balance sooner. As a result, we now anticipate cellulose specialty EBITDA to be in the range of $237 million to $245 million. In cellulose commodities fluff demand remains generally strong. Although, we anticipate earnings pressure due to the significant Chinese tariff. These impacts will be offset by diversifying our sales channels into non-tariff affected markets, and shifting production to alternate commodity grades. Taking these factors into account, we project cellulose commodity EBITDA, to be approximately a negative $5 million for the year. Our biomaterial business is anticipated to deliver modest, but positive EBITDA growth driven by contributions from our France bioethanol and powder lignosulfonate facilities, and ongoing strategic investments. We expect biomaterials 2025, EBITDA to be in the range of $8 million to $10 million, and paperboard volumes are expected to modestly improve, benefiting from improved market access within North America. However, prices remain under pressure, due to competitive market dynamics including the startup of new capacity. As a result, we expect paperboard EBITDA, to be approximately $25 million for 2025. Turning to high-yield pulp persistent oversupply continues, to create challenging market conditions. In response, we plan to idle one of our high-yield pulp production lines, for 11 weeks starting in early June. We anticipate the segment's EBITDA to be approximately a negative $20 million this year. Corporate costs, are expected to increase year-over-year, primarily driven by the non-cash environmental reserve charge, and foreign exchange headwinds, partially offset by reduced costs following the completion of our ERP implementation. Overall, we now expect corporate expenses of $70 million for 2025. Lastly, on Slide 16, we are targeting a net secured leverage ratio of approximately 3.1 times covenant EBITDA for year-end 2025, which is well within our debt covenants and remains within striking distance of our long-term objective of less than 2.5 times. Despite the current market uncertainties, we are confident that we will achieve our longer term EBITDA target of $325 million, because the growth and value drivers of our strategy remain intact. Our highly bespoke products in a supply constrained market allow us to execute our value over volume CS strategy. The investment in low risk, but high return cost reduction projects will increase profit margins, and improve our long-term competitive advantage. Our exposure to the non-fluff commodities market will decrease as key cellulose specialties and uses grow, and we continue to strongly believe that the biomaterial strategy is independent of the current tariff risk, and thus remains a valuable growth opportunity for RYAM. With that operator, please open the call to questions.